Location of Repository

Control of the EBV growth transformation programme: the importance of the Bamhi W repeats

By Kuan-Yu Kao

Abstract

Epstein-Barr virus (EBV), a human gammaherpesvirus, possesses a unique set of latent genes whose constitutive expression in B cells leads to cell growth transformation. The initiation of this B-cell growth transformation programme depends on the activation of a viral promoter, Wp, present in each tandemly arrayed BamHI W repeat of the EBV genome. In order to examine the role of the BamHI W region in B cell infection and growth transformation, we constructed a series of recombinant EBVs carrying different numbers of BamHI W repeats and carried out B cell infection experiments. We concluded that EBV requires at least 2 copies of BamHI W repeats to be able to activate transcription and transformation in resting B cells in vitro. At least 5 copies of BamHI W were required for optimal transcription and transformation; while increasing the number beyond 5 copies had no further effect. Experiments to try to rescue the impaired virus indicated that the expression of sufficient levels of EBNA-LP and EBNA2 from Wp are the key determinants of virus-driven B cell transformation. We believe that EBV has evolved to contain multiple copies of BamHI W repeats to ensure high levels of Wp-initiated transcripts immediately post infection

Topics: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Year: 2011
OAI identifier: oai:etheses.bham.ac.uk:1493

Suggested articles

Preview

Citations

  1. (1962). A children's cancer dependent on climatic factors.
  2. (1992). A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2.
  3. (1958). A sarcoma involving the jaws in African children.
  4. (1998). Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1).
  5. (1981). Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines.
  6. (1998). Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol13-acetate-induced phosphorylation.
  7. (2002). Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. doi
  8. (1995). An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene.
  9. (1986). An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines.
  10. (1991). An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator.
  11. (2001). An Epstein-Barr-related herpesvirus from marmoset lymphomas.
  12. (2006). Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
  13. (1996). Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.
  14. (2003). B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.
  15. (1999). CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.
  16. (1993). Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences.
  17. (1998). Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter.
  18. (1998). Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
  19. (1982). Characterization of the major Epstein-Barr virusspecific RNA in Burkitt lymphoma-derived cells.
  20. (1990). cis-acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site.
  21. (2002). Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.
  22. (1992). Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells.
  23. (1996). Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
  24. (1982). Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region.
  25. (1989). Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization.
  26. (2001). Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
  27. (1998). Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related nonHodgkin's lymphomas.
  28. (1998). Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.
  29. (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
  30. (1991). Early events in Epstein-Barr virus infection of human B lymphocytes. doi
  31. (2003). EBNA3A association with RBP-Jkappa downregulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.
  32. (1994). Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes. doi
  33. (1980). Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping.
  34. (1993). Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells. doi
  35. (1993). Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
  36. (2008). Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing.
  37. (1975). Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. doi
  38. (1989). Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. doi
  39. (1992). Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
  40. (1990). Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.
  41. (2006). Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed.
  42. (1986). Epstein-Barr virus mRNAs produced by alternative splicing. doi
  43. (2006). Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling.
  44. (1990). Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.
  45. (1996). Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA.
  46. (1992). Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
  47. (1989). Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
  48. (1991). Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
  49. (2008). Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.
  50. (2005). Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. doi
  51. (1984). Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.
  52. (2005). Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro.
  53. (1990). Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.
  54. (1987). Epstein-Barr virustransformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes.
  55. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
  56. (1999). Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood.
  57. (1991). Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients.
  58. (1991). Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia.
  59. (1995). Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. doi
  60. (1999). Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
  61. (1998). Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease.
  62. from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide.
  63. (2003). Functional interaction of nuclear factor y and sp1 is required for activation of the epstein-barr virus C promoter. doi
  64. (1993). High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. doi
  65. (2000). High levels of EpsteinBarr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders.
  66. (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
  67. (1997). Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus.
  68. (2006). Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.
  69. (2009). Implications of chimaeric non-co-linear transcripts.
  70. (2005). Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
  71. (1991). Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.
  72. (1988). Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
  73. (2003). Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.
  74. (1997). Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.
  75. (1981). Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments.
  76. (1987). Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.
  77. (1994). Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.
  78. (1965). Morphological and Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt's Lymphoma.
  79. (1995). Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus.
  80. (2006). Multiple domains of EBER 1, an Epstein-Barr virus noncoding RNA, recruit human ribosomal protein L22.
  81. (1990). Novel transcription from the EpsteinBarr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma.
  82. (1984). Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein.
  83. (1972). Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis.
  84. p53 is frequently mutated in Burkitt's lymphoma cell lines.
  85. (1991). p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
  86. (1998). Pathogenesis of AIDSrelated lymphomas: molecular and histogenetic heterogeneity.
  87. (1993). Posttransplantation lymphoproliferative disorders.
  88. (1998). Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.
  89. (1997). Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder.
  90. (2005). Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts.
  91. (2000). Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.
  92. (1977). Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination.
  93. (1987). Replication of latent Epstein-Barr virus genomes in Raji cells. doi
  94. (1994). Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.
  95. (2004). Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or EpsteinBarr virus latency III-infected cells.
  96. (1989). Size and stability of the Epstein-Barr virus major internal repeat (IR-1) in Burkitt's lymphoma and lymphoblastoid cell lines. doi
  97. (1990). Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
  98. (1993). The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events.
  99. (1999). The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHIQ promoter activity.
  100. (1995). The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders.
  101. (2000). The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.
  102. (2009). The LMP1 promoter can be transactivated directly by NF-kappaB.
  103. (1993). Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.
  104. (1988). Transformation of Balb 3T3 cells by the BNLF1 gene of Epstein-Barr virus.
  105. (1989). Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B.
  106. (1999). X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.